Posted by Michael Wonder on 13 Feb 2025
Keytruda gets expanded coverage for 11 indications at cancer disease panel
13 February 2025 - After nearly two years of stalled discussions, the Keytruda (pembrolizumab) reimbursement expansion debate has finally begun.
The Cancer Disease Review Committee under the HIRA set reimbursement standards for 11 of Keytruda's 17 indications.
